The concentration dose response for aryl hydrocarbon receptor (AHR)-mediated CYP1A1 and CYP1A2 messenger RNA (mRNA) induction and enzyme activity was determined in primary cultures of rat and human hepatocytes for 2, 3,7,8-tetrachlorodibenzo-p-dioxin, 2,3,4,7,8-pentachlorodibenzofuran, and 2,3,7,8-tetrachlorodibenzofuran. Eleven different congener concentrations from 0.00001 to 100nM were used, thus spanning seven orders of magnitude. The Hill model was used to obtain values of EC x and maximal response from the individual data sets. No-observed effect concentration values were derived using several statistical methods including Dunnett's test, the WelchAspin test, and step-down bilinear regression. Thresholds were estimated using baseline projection methods and a ''hockey stick'' fitting method. Human hepatocytes were less responsive and less sensitive with respect to CYP1A1 activity and mRNA induction than rats. On the other hand, the human CYP1A2 response was more robust than the response in rats but generally less sensitive. These data allow an evaluation of relative species sensitivities for developing interspecies toxicodynamic adjustment factors, for assessing AHR activation thresholds, and for evaluating relative congener potencies. Overall, these data support the position that humans are less sensitive than rats to these AHR-dependent end points and support the use of a dataderived adjustment factor of 1.0 or less for extrapolating between rats and humans.
In vitro studies and studies in mouse models expressing the human aryl hydrocarbon receptor (AHR) have shown humans to be less sensitive to dioxins than rats and mice due to differences in ligand affinity and AHR function (Connor and Aylward, 2006; Drahushuk et al., 1996 Drahushuk et al., , 1999 Moriguchi et al., 2003; Schrenk et al., 1995; Silkworth et al., 2005) . The AHR amino acid sequences deduced from complementary DNA (cDNA) and protein databases, and single-nucleotide polymorphisms in the ligand-binding domain of the human AHR, indicate that the human AHR demonstrate a lower dioxin affinity than rats (Ema et al., 1994; Procopio et al., 2002; Rowlands et al., 2008) . Epidemiological and clinical data on populations or individuals exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) or other dioxin-like chemicals (DLCs) likewise indicate that humans are less sensitive than rodents (Abraham et al., 2002; Aylward et al., 2008; Guzelian et al., 2006; Halperin et al., 1995) .
Cytochrome P450 1A (CYP1A) induction is one of the most sensitive AHR activation end points (Drahushuk et al., 1996; Gaylor and Aylward, 2004; Tritscher et al., 1992) . Dosages as low as 0.15 ng/kg/day, resulting in whole-body concentration of 2.8 ng/kg TCDD in mice or a single gavage dose of 1 ng/kg in female Sprague-Dawley rats, induced a statistically significant increase in ethoxyresorufin-O-deethylase (EROD) activity (Diliberto et al., 2001; Vanden Heuvel et al., 1994) . Wet weight hepatic tissue concentrations as low as 8 ppt have been reported to induce CYP1A1 in rats (Drahushuk et al., 1996) . Whole-body dosages of 1-2.8 ng/kg roughly equate to a lipidadjusted TCDD blood concentrations of 4-10 ppt in humans, which is within the range of background blood dioxin concentrations, especially for younger adults Chen et al., 2010; Ferriby et al., 2006; Hedgeman et al., 2009) .
Because of the uncertainties in extrapolation of DLCs from rats to humans, dose-response comparisons between normal human and rat cells or tissues are highly desirable. In vitro CYP1A1 and CYP1A2 induction in primary human and rat hepatocytes could provide a functional dose metric useful for interspecies extrapolation (e.g., Schrenk et al., 1995; Silkworth et al., 2005; Xu et al., 2000) . Of these studies, only Silkworth et al. (2005) used concentrations low enough to characterize CYP1A responsiveness at the current human background exposure levels.
The authors certify that all research involving human subjects was done under full compliance with all government policies and the Helsinki Declaration.
To provide additional risk assessment data for DLCs (TCDD, 2, 3, 4, 7, , and 2, 3, 7, ), CYP1A induction in human and Sprague-Dawley rat primary hepatocytes was evaluated using a robust concentration regimen. SpragueDawley female rats were selected since liver tumor data from cancer bioassays using this strain provide the current data for a number of cancer potency derivations (Kociba et al., 1978; Maruyama and Aoki, 2006 Simon et al., 2008 Simon et al., , 2009 . 4-PeCDF is of interest with its highest Toxic Equivalency Factor (TEF) value (0.3) of all the furan congeners, and its notable hepatic accumulation in rats due to CYP1A2 sequestration with dose metric-dependent impacts on relative potency estimates (Budinsky et al., 2006; DeVito et al., 1998; Diliberto et al., 1997; NTP, 2006b; van den Berg et al., 2006) . TCDF is of interest due to its structural similarity to TCDD and its relatively short half-life in the presence of CYP1A1 induction due to oxidative metabolism McKinley et al., 1993; Olson et al., 1994; Tai et al., 1993; Zwiernik et al., 2008) . All three congeners were evaluated over a seven-order of magnitude concentration range encompassing 11 concentrations. The large concentration range used in this study provides robust data for developing species' specific chemicalspecific adjustment factors as described in World Health Organization-International Programme on Chemical Safety (WHO-IPCS; and for contributing to TEF derivation van den Berg et al., 1998 van den Berg et al., , 2006 . In addition, CYP1A activation could anchor the lower bound of risk characterization for dioxins, i.e., exposures that are below a level required for sufficient AHR activation to induce CYP1A will be below the dose needed for downstream, dose-dependent transitions, and eventual toxicity.
MATERIALS AND METHODS
Materials. PBSwas purchased from Invitrogen (Gibco, Grand Island, NY Isolation of primary hepatocytes. Primary cultures of human hepatocytes were prepared from remnants of normal resected liver tissue from five women aged 44-77 years (Table 1) . The research was carried out in accordance with the principles of the current version of the Helsinki Declaration. Each donor fully consented under an institutional review board application approved by the individual institutions where liver resection surgery was conducted. The resected remnants were determined disease free by a board certified pathologist. Four of the five human donors did not consume alcohol, and all were free of hepatitis and HIV. Rat hepatocytes were obtained from five 10-week-old individual female Sprague-Dawley rats. Preplating cell viability, determined by trypan blue exclusion, ranged from 82 to 93% in human and 90 to 94% in rat hepatocytes (Table 1) .
Following isolation, hepatocytes were resuspended in DMEM containing 5% fetal calf serum, insulin (4 lg/ml), and dexamethasone (1lM) and added to 24-well BioCoat (BD Biosciences) plates coated with simple collagen type 1 substratum and allowed to attach for 3-6 h at 37°C in a humidified chamber with 95% relative humidity/5% CO 2 . After attachment, culture vessels were swirled and medium containing debris and unattached cells were aspirated. Fresh ice-cold serum-free DMEM/Ham's F12 containing 50nM dexamethasone, 6.25 lg/ml insulin, 6.25 lg/ml transferrin, 6.25 ng/ml selenium (ITSþ), and 0.25 mg/ml Matrigel were added to culture vessels, which were immediately returned to the humidified chamber. Medium was kept in the dark prior to use and was not changed during the incubation periods. It has been shown that freshly isolated hepatocytes overlaid with an extracellular matrix component such as Matrigel or collagen retain the ability to respond to prototypical cytochrome P450 and phase II inducers (LeCluyse, 2001 , LeCluyse et al., 2000 . Cultures of hepatocytes were typically maintained 36-48 h prior to initiating experiments with TCDD, 4-PeCDF, or TCDF. 3-MC has been historically used to evaluate CYP1A responsiveness of human and rat primary hepatocytes at 2 and 1lM, respectively. However, in these experiments, TCDD was used as its ''positive control'' because it was found to be a more efficacious and potent inducer for verifying CYP1A responsivity.
Cell viability and incubations with TCDD, 4-PeCDF, and TCDF. Human and rat hepatocytes cultures were exposed for 48 h to TCDD, 4-PeCDF, and TCDF concentrations ranging from 0.00001 to 100nM. Cell viability was assessed 24 and 48 h after addition of TCDD, 4-PeCDF, and TCDF at the higher test concentration of each test article and vehicle control by morphological appearance, LDH leakage, ATP levels, and phase contrast microscopy (LeCluyse et al., 2000; Meunier et al., 2000 ; Promega Test Kits for LDH and ATP according to manufacturer directions). No treatment-related increases in LDH release were observed. Mean ATP concentrations in test compound-treated rat hepatocytes ranged from 9 to 11lM at 24 and 48 h, respectively, and were comparable with control values. Human hepatocytes exhibited threefold greater ATP concentrations than rats, and there were no treatment-related reductions in ATP levels. Overall, cell viability end points did not demonstrate treatment-related cytotoxicity.
CYP1A1 and CYP1A2 enzyme activities. After 48-h of congener treatment, the culture medium was aspirated and the cell monolayers were rinsed once with HBSS. Cell culture medium 10lM ethoxyresorufin or 100lM phenacetin was added to the wells to assess CYP1A1 and CYP1A2 activity as EROD and phenacetin-O-deethylase (POD) to form acetaminophen, respectively (Jackson et al., 2009) . Total protein content from each well was determined to normalize enzymatic activity using the BCA Protein Determination Kit (Pierce, Rockford, IL).
Cyp1A1 and Cyp1A2 messenger RNA expression level determinations. Upon termination of the 24-h TCDD treatment period, cells (24-well format) were washed with one volume of HBSS and lysed by addition of 0.35 ml of ABI Nucleic Acid Lysis Solution (Applied Biosystems, Foster City, CA) and frozen at À70°C. Lysates were thawed and total RNA was isolated from each sample using an ABI 6100 prepstation. qRT-PCR was conducted in a two step process with 200 ng of total RNA for each of the four individual replicate wells. First, cDNA was generated using the High-Capacity cDNA Archive Kit (Applied Biosystems). From each individual RT reaction, 2 ll of cDNA was added to 20 ll qPCRs using gene-specific TaqMan primer/probe sets (Applied Biosystems). Glyceraldehyde-3-phosphate dehydrogenase messenger RNA
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(mRNA) served as the endogenous control gene for normalization to obtain relative-fold mRNA (Pohjanvirta et al., 2006) .
Statistics and dose-response analysis. Four replicates were performed at each concentration of congener for determining EROD, POD, and CYP1A1 and CYP1A2 mRNA. Individual human or individual rat data were fit to Hill models, and the parameters were averaged across the members of the species (Table 2 ; Supplementary tables 11-21). No-observed effect concentration (NOEC) values were estimated using step-down linear regression, Dunnett's test, and the Welch-Aspin test for data combined across individuals.
Step-down linear regression was also used to obtain NOEC values for individuals (Supplementary methods and Supplementary tables 5-7). Four baseline projection methods were used to estimate thresholds (Goutelle et al., 2008; Lutz and Lutz, 2009; Silkworth et al., 2005 ) (see Supplementary methods for additional information).
RESULTS

EROD and POD Induction Efficacy
Hill model fits for all three congeners demonstrated concentration-related induction of EROD and POD activities for all three congeners (Table 2 , Fig. 1 , Supplementary tables 1 and 11-13). There was no statistically significant effect with 0.1% DMSO on EROD or POD induction when compared with media-treated controls (data not shown). From Hill model fits to individual data, the average human B max values for TCDDinduced, 4-PeCDF-induced, and TCDF-induced EROD were 88.2, 86.5, and 91.6 pmol/min/mg, respectively (Table 2 ). In rats, the average B max values for TCDD-induced, 4-PeCDFinduced, and TCDF-induced EROD were 253, 238, and 263 pmol/min/mg, respectively. Thus, there was a threefold reduced efficacy in humans compared with rats for all three congeners. Humans and rats responded similarly in terms of POD induction, with B max values for TCDD, 4-PeCDF, and TCDF of 840, 690, and 415, respectively, in humans and 355, 348, and 295, respectively, in rats. Although the Hill model successfully fits the individual TCDF POD induction responses, a visual inspection of the data would suggest that the maximal response had not been attained at 100nM TCDF ( Fig. 1) . For TCDF-induced POD activity, the human EC 50 estimated as the average model parameter from individual fits was 1.18nM and the corresponding rat value was 0.25nM (Table 2 ). It is likely that the fits to the rat data were poor because the rat hepatocytes did not appear to achieve a maximal response (Fig. 1) . TCDF concentrations greater than 100nM might be necessary to maximally express TCDF-induced POD induction in rats. On the other hand, TCDF's response may be blunted secondary to increased CYP1A1 4-hydroxylation McKinley et al., 1993; Olson et al., 1994; Tai et al., 1993; Zwiernik et al., 2008) . Because TCDF's EC 50 derivation for POD activity may be compromised by a lack of a true asymptotic, maximal response in these experiments, one could select other points of departure along the dose-response range, e.g., EC 05 estimates-see Supplementary table 10-which shows comparable responsiveness between rats and humans.
Cyp1A1 and Cyp1a2 mRNA Expression Efficacy
Rat and human hepatocytes demonstrated concentrationrelated relative fold increases for Cyp1A1 and Cyp1a2 mRNA expression to the three congeners (Table 2 ; Fig. 2 ; Supplementary tables 3 and 14-16). There was no statistically significant change with 0.1% DMSO when compared with media-treated controls for either gene (data not shown). Large differences were observed between rats and humans for basal CYP1A1 mRNA expression, whereas for CYP1A2, the differences were much smaller being within an approximate order of magnitude of each other. Rat hepatocytes exhibited a baseline Cyp1A1 mRNA relative-fold expression from 4.74 to 93.7 across the three congeners, whereas human hepatocytes exhibited a much lower baseline relative fold expression ranging from 0.08 to 0.43. For Cyp1a2 mRNA, rat hepatocytes exhibited a baseline relativefold expression that ranged from 15.4 to 24.4 across the three congeners versus 1.4 to 11.6 in humans.
In human primary hepatocytes, the maximal fold induction of CYP1A1 mRNA showed the following relationship: TCDD > 4-PeCDF > TCDF. The rat response, however, was relatively comparable for all three congeners. From Hill model fits to individual data (Table 2) , it was determined that rats responded with 5 to 10 times greater induction of Cyp1A1 mRNA across the three congeners compared with humans. Whereas for CYP1A2 mRNA, humans responded to a much greater extent compared with rats, and this was consistent with the observations for POD activity (Table 2) . Although rat CYP1A1 mRNA induction for all three congeners was notably more responsiveness in the low concentration range, the human and rat CYP1A2 mRNA induction response was fairly similar at low concentrations.
Species Differences in Sensitivity
EROD and POD sensitivity differences. Human hepatocytes were less sensitive to the induction of EROD and POD activities relative to rats. The EC 50 values determined from Hill model fits to the individual human and rat data are summarized in Table 2 . For EROD activities, humans were approximately 50-, 30-, and 70-fold less sensitive to TCDD, 4-PeCDF, and TCDF than rats, respectively. Comparing POD activity, humans were approximately 20-, 3-, and 5-fold less sensitive to TCDD, 4-PeCDF, and TCDF than rats, respectively.
Cyp1A1 and Cyp1a2 mRNA sensitivity differences. The Cyp1A1 mRNA sensitivity comparison between rat and human hepatocytes differed from EROD activity induction for 4-PeCDF but was comparable for TCDD and TCDF ( Table 2 ). The average human EC 50 values for TCDD, 4-PeCDF, and TCDF were 0.37, 0.67, and 2.02nM, respectively and for rats, the values were 0.012, 0.43, and 0.09nM, respectively. Hence, with regard to Cyp1A1 mRNA expression, humans appear about 30-and 20-fold less sensitive to TCDD and TCDF than rats but about equally sensitive to 4-PeCDF as rats. However, the magnitude of the rat EROD and CYP1A1 response was much greater than the human response.
With respect to Cyp1A2 mRNA induction, 4-PeCDF produced a response of comparable sensitivity in both rat and human hepatocytes. The average EC 50 values were 0.33, 0.43, and 1.27nM in humans and 0.06, 0.58, and 0.09nM in rats for TCDD, 4-PeCDF, and TCDF, respectively. Thus, humans were approximately 5-and 15-fold less sensitive than rats to TCDD and TCDF and about equally sensitive to 4-PeCDF as rats.
Transcriptional and Translational Effects
To examine dose-related effects on both mRNA and protein, a ''gain factor'' or fold induction for either mRNA or enzyme activity (EROD or POD) was calculated by dividing the individual DMSO control value into the individual concentration response for all three chemicals and all four biochemical measures. Plots of gain factors for mRNA and for their respective enzyme activities averaged over the individual humans and rats versus concentration are shown in Figure 3 and Supplementary tables 22-27. In all cases, the ratio of the mRNA gain to enzyme activity gain factor designated as the ''Gain Ratio'' in Supplementary tables 22-27 was generally greater in rats being near or above 1.0. The rat gain ratio slightly increased in the region of the monotonic increase in CYP1A induction but declined slightly toward 1.0 in the range of the maximal response. In contrast, the human gain ratio declined from 1.0 in the monotonic increase range for CYP1A induction.
The ''enzyme activity gain factor'' is based on the fold induction of EROD and POD activities and represents the integration across transcription and translation (Table 3) . For the overall gain of CYP1A1 (EROD fold induction), rats achieved the 10-fold and 100-fold response at lower concentrations than humans. For POD's overall gain, however, rats and humans were comparable at the 10-fold increase but never did achieve a 100-fold overall gain nor did human liver cells treated with TCDF.
Finally, we examined the EC 50 ratios between enzyme activity and mRNA (Table 3 ). This ratio can be thought of as a ''coupling efficiency'' between the concentrations required to induce transcription and the final output in enzyme activity (indirect measure of protein). The coupling efficiency estimates show humans to be closer to unity than rats except for TCDF CYP1A1 and CYP1A2. The TCDF value may be impacted by CYP1A2-mediated clearance of TCDF, but data on the metabolic clearance of TCDF in these cell culture studies were not obtained to evaluate this possibility.
Analysis of NOECs and Thresholds and Relative Potencies
From averages of individual data and from the data on each individual, NOEC values were estimated using Dunnett's test, the Welch-Aspin test, and step-down linear regression (noted as ''LinReg'' in Tables 5-7, Supplementary material). In almost all cases, with the exception of 4-PeCDF-induced CYP1A2 mRNA, the human NOEC was greater than or equal to the rat NOEC. Threshold estimates based on a number of other approaches and for each individual subject and rat can be found in Supplementary tables 8-10. Human hepatocytes were 4-53 times less responsive than rat hepatocytes for TCDD and TCDF based on the median estimate of the threshold. The one exception was for 4-PeCDF-induced Cyp1A2 mRNA where the human-to-rat ratio of the medians yielded a value of~0.8, suggesting comparable responsivity with respect to a threshold response. The EC 50 values for TCDD, 4-PeCDF, and TCDF (as shown in Table 2 ) were used to derive relative potency estimates (ReP) ( Table 5) . We have also provided EC 10 estimates from the data shown in Table 2 in the event relative potencies are of interest from another area of the dose-response curve (Table 4) . Overall gain is the enzyme activity at a specific concentration divided by the DMSO control value and simply represents fold induction over control levels. Ratio of EC 50 for enzyme activity/EC 50 mRNA (from Table 2 Hill fits). 
DISCUSSION
Four biomarkers of CYP1A induction were measured in female primary human and rat hepatocytes across a wide range of congener concentrations. Our results are generally consistent with those other studies of primary human hepatocytes (Drahushuk et al., 1996 (Drahushuk et al., , 1998 Kishida et al., 2008; Richert et al., 2009; Schrenk et al., 1995; Silkworth et al., 2005; Vrzal et al., 2008 Vrzal et al., , 2009 Xu et al., 2000) . A comparison of our EC 50 estimates to those from the Silkworth et al. (2005) paper is provided in Table 7 . These results provide useful risk assessment information since they reflect the sex and strain of rat used in dioxin cancer risk assessments (Kociba et al., 1978; OEHHA, 2005 ; U.S. Environmental Protection Agency, 2002). The data allow for derivation of intraspecies and interspecies chemical-specific adjustment factors and relative potency estimates germane to TEFs (e.g., van den Berg et al., 2006; WHO-IPCS, 2005) . Ratios between human and rat EC 50 values and between median human and rat threshold values in Table 2 were calculated as preliminary estimates of the interspecies chemical specific adjustment factors (CSAF) for toxicodynamics (Table 6 ). For all end points, humans were generally less responsive, i.e., CSAF < 1.0 than rats versus a typical default assumption where a CSAF of 10 is adopted. Regarding studies done in liver cell lines, these studies may not be relevant for risk assessment purposes because transformed cells may not respond in a ''normal'' or in vivo-like manner to AHR activation (Zhang et al., 2006) . For example, Zhang et al. (2006) demonstrated greater CYP1A1 induction than CYP1A2 induction in HepG2 cells, which was opposite of the CYP1A2 predominance in primary human hepatocytes, e.g., the HepG2 cells respond more like rat primary hepatocytes.
Except for 4-PeCDF Cyp1A2 responses where human and rats were somewhat similar, our results generally show that rats were more sensitive to CYP1A induction (EC 50 basis). Our data are consistent with the position that human are 10 times less sensitive than rats for this very sensitive AHR activation end point (Connor and Aylward, 2006) . Therefore, animal-tohuman toxicodynamic adjustment factors of less than 1.0 are proposed (e.g., Simon et al., 2009; WHO-IPCS, 2005) . Key uncertainties and assumptions made in drawing this conclusion include the implicit assumption that these chemicals enter the cells and distribute to cellular components of rat cells and human cells equally, that the concentrations in medium are indeed concentrations in the cells (see below for more discussion), and that the measured response in humans and rats (mRNA and activity) are integrated outcomes of AHR ligand binding and downstream AHR-receptor interactions with DNA and coregulatory proteins.
The greater human CYP1A2 response is relevant to attempts for extrapolating between rats and humans concerning questions about tissue dosimetry, evaluation of TEF values, and quantitative interspecies extrapolation (e.g., Budinsky et al., 2006) . Greater CYP1A2 induction and sequestration may (1) reduce free cytosolic congener available for AHR binding, (2) serve as a continuing reservoir of ligand resulting in chronic AHR activation, or (3) reduce the bioactivation of carcinogenic PAHs in human hepatocytes compared with rats (DeVito et al., 1998; Diliberto et al., 1997; Zhang et al., 2006) . In the first scenario, greater CYP1A2 sequestration in humans may render the congener unavailable to tissues that are distal to the dietary portal of entry for dioxins or reduce AHR activation in the liver. In the second scenario, hepatic CYP1A2 induction and sequestration may place humans at greater risk than rats for liver cancer, although there is no evidence of increased hepatic tumors among former trichlorophenol workers who were exposed to TCDD (Collins et al., 2009) . With respect to reproductive/developmental toxicity, greater hepatic CYP1A2 sequestration could conceivably prevent distribution of the sequestered PCDD/F to the fetal compartment (Aylward et al., . An interesting exercise is to speculate how these in vitro results extrapolate to in vivo TCDD exposures. In Supplemental table 28, we show calculated rat and human dosages representing a number of the in vitro dose-response estimates. These estimates are based on the TCDD liver tissue uptake data from Drahushuk et al. (1996 Drahushuk et al. ( , 1999 and pharmacokinetic modeling. For example, the in vitro human TCDD EROD threshold of 0.013nM corresponds to an estimated daily intake dosage of TCDD of 99.7 ng/kg/day. The estimated U.S. average daily toxic equivalency quotient (TEQ) intake of dioxin from meats ranges from 0.0001 to 0.0003 ng/kg/day TEQ-yielding ratios between the estimated intake dose linked to in vitro CYP1A induction to background dietary exposures of 332,333 to 997,000 (Huwe and Larsen, 2005) . However, these ratio estimates seem high; actual data on dioxin uptake into hepatocytes will be required to provide greater confidence in such an in vitro to in vivo extrapolation. For additional perspective, 1000 ppt lipid-adjusted serum TEQ has been identified as a threshold value for CYP1A2 induction in humans (Abraham et al., 2002; Guzelian et al., 2006) . Thousand parts per trillion lipid-adjusted serum levels reflect daily TCDD dosages of 0.7 ng/kg/day, yielding a ratio of 2333 when compared with the 0.3 pg/kg/day average TEQ intake from meat.
The gain factor analysis provides for examination of how transcription, translation, and CYP1A enzyme activity are linked. mRNA accumulation likely represents a quantitative indicator of gene transcription since, at 24 h, induced levels for CYP1A mRNA are largely due to changes in gene transcription (Barker et al., 1992; Till et al., 1999) . CYP1A enzyme activity is highly correlated with protein expression in rat liver and in hepatocytes, but these data were not acquired during these studies (Liu et al., 2001; Meredith et al., 2003; Ooe et al., 2006) . However, EROD and POD activity which are indirect indicators of protein expression and the gain factors for enzyme activity induction represent overall gain relative to combined mRNA accumulation and translation. Hence, the ratio of these two gain factors represents a mix of translation, posttranslational processing, and regulation of enzyme activity. The ratio of the mRNA and the enzyme activity (EROD/POD) gain factors in rats across the concentration response is~1, and thus, the overall gain is dependent on transcription and accumulation of mRNA (dashed blue lines in Fig. 3 ; Supplementary tables 22-27). Not so in humans, -the ratio is consistently less than 1 for all the three chemicals and both enzyme pathways and decreases even further as concentration-dependent increases in mRNA transcription occur. The human and rat difference in the relative gain for CYP1A activity expression requires further study and raises additional questions. For example, as the AHR receptor is maximally activated in humans, do the humans possess secondary regulatory responses that maintain greater control over the overexpression of CYP1A activity relative to CYP1A mRNA increases, e.g., gain is blunted in humans, whereas it is less so in rats? Do differences in mRNA stability explain the loss of gain in expression of CYP1A activity? The difference in ''gain'' may represent a fundamental difference in regulation of translation and/or enzyme activity between humans and rats. On the other hand, the coupling efficiency between mRNA and CYP1A activity induction, based on EC 50 estimates, are closer to unity in humans, whereas the rat coupling efficiency is less. This suggests the human mRNA CYP1A activity is more closely coordinated in terms of dose response.
The constitutive (baseline) activity of CYP1A1 and CYP1A2 deserve a few comments. For example, the mean non-induced human EROD activity across all three congeners was 0.11 pmol/min/mg, about 200-fold lower than Meunier et al. (2000) , who reported a non-induced value of 21 pmol/ min/mg in a 49-year-old male. Differences in naturally occurring AHR ligands unaccounted for in cell medium (DMEM/Ham's F12 used here vs. Ham's F12/Williams E medium with 10% decomplemented fetal calf serum) could be one explanation. Hepatic CYP1A2 activity shows greater constitutive expression than does CYP1A1 activity (Drahushuk et al., 1996; Kishida et al., 2008; Schweikl et al., 1993) . The human mean POD baseline activity across all three congeners was 5.54 pmol/min/mg. Meunier et al. (2000) reported noninduced POD activity of around 200 pmol/min/mg from a 47-year-old female subject. Naturally occurring AHR ligands are present in human blood at significant concentrations (Connor et al., 2008; Schecter et al., 1999) . Could the differences between basal CYP1A1 and CYP1A2 activity reflect differences in naturally occurring AHR ligands in the media? On a final note, intraspecies variation in both baseline and maximal responses were fairly large. These likely represent both intra-individual variation and possibly experimental differences contributing to this variation in efficacy. However, there was much lower intraspecies variation in EC 50 values reflecting sensitivity, which are the values used for CSAF and TEF determination (Table 2) . Since dioxin risk assessments almost always involve mixtures where congeners other than 2,3,7,8-TCDD provide the significant proportion of the mixtures total toxic equivalence, the issue of relative potency is important Van den Berg et al., 1998 . Both 4-PeCDF and TCDF were generally less potent than TCDD based on an EC 50 basis, but an in-depth analysis to determine whether the congeners exhibited parallel dose-response curves was not conducted (e.g., Budinsky et al., 2006; Walker et al., 2005) . CYP1A induction has limitations as the basis for TEFs because it is likely a well-conserved adaptive response that may be unrelated to the potential adverse effects of excessive and sustained AHR activation (Mitchell and Elferink, 2009) .
In summary, this study generated complete dose-response data sets for CYP1A1 and CYP1A2 induction. The comparisons between humans and rats provide useful information to develop chemical-specific adjustment factors for interspecies extrapolations and relative potency assessments. Because CYP1A induction can represent an adaptive response, the use of these findings in developing species-specific uncertainty factors for cancer and noncancer risk assessment is likely conservative and protective; although the CYP1A induction response is evolutionarily conserved across species, it is unlikely that toxicity is similarly conserved. Overall, the intraspecies and cross-species comparisons using CYP1A responsiveness allow for an assessment of AHR activation using one of the most sensitive dioxin responses known to date. As previously reported, the rat CYP1A1 response was greater than the human response. On the other hand, humans demonstrated a greater maximal induction of CYP1A2 to these three congeners, but humans were generally less responsive (threshold/NOEC) and less sensitive (EC 50 ) with regard to CYP1A2 induction. Overall, the data do not support the proposition that humans are more sensitive than rats, thereby requiring an extrapolation uncertainty factor greater than 1.0. The data do support a species-specific uncertainty factor for across-species extrapolation of 1.0 or less. 
